March 2021 - 4D Lifetec in the media

Please read the article on the startupticker.ch platform from 05.03.2021.

February 2021 - 4D Lifetest™: High sensitivity confirmed for the diagnosis of breast cancer

After positive results from our clinical validation studies in lung and prostate cancer in the past months, we have now also been able to successfully complete the breast cancer cohort.

February 2021 - 4D Lifetec in the media

The Swiss Biotech Association has listed our latest news.

January 2021 - More 4D Lifetec in the media

Please read the article in the DeciBio Weekly Liquid Biopsy Digest from 21.01.2021

January 2021 - 4D Lifetec in the media

Please read the article in GenomeWeb from 05.01.2021

January 2021 - Press Release on new cooperation agreement

We are very pleased to announce that we have signed a cooperation agreement with VolitionRX to validate a completely novel concept for the use of liquid biopsies in cancer diagnostics.

November 2020 - 4D Lifetec publishes first clinical results at the 39th World Cancer Conference

In an observational study 'Prospective Evaluation of 4D Lifetest^TM Parameters to Develop a Universal Early Cancer Diagnosis Test', blood samples from 39 participants were collected (49% patients with newly diagnosed, untreated lung cancer and 51% non-cancer). Evaluation of our DDS biomarker (DNA Damage Sensitivity) comparing non-cancer with cancer samples resulted in more than 90% sensitivity at 95% specificity (95% CI: 76.4-99.7%) across all stages.

October 2020 - 4D Lifetec files new patent for its cancer biomarker DNA Damage Sensitivity (DDS)

4D Lifetec filed a new patent to make the powerful cancer biomarker DDS part of its proprietary technology.

May 2020 - Preliminary Clinical Study Results show Outstanding Sensitivity of 4D Lifetest™ for Lung Cancer Detection

Preliminary results of the clinical study on the diagnosis of lung cancer patients show 4D Lifetest™ having a competitive or better sensitivity and specificity compared to leading diagnostic biomarkers for lung cancer.  This is really another important breakthrough on the way to an effective multi-cancer assay.

March 2020 - In-vivo proof of concept for 4D Lifetest™ approved

We congratulate the entire team of the company for reaching this extremely important milestone.

January 2020 - 4D Lifetec bridges over into the USA and says thank you

With many exciting discussions at the JPM conference in San Francisco, 4D Lifetec has started to focus on the USA market entry.

December 2019 - First positive clinical results on cancer detection by 4D Lifetest™

We are very pleased that we were able to close the year 2019 with positive results. The results confirms our conviction that the 4D Lifetest^TM will soon reach the next important milestone.

October 2019 - 4D Lifetest™ has successfully entered into clinical study

After reaching Proof of Technology in August the 4D Lifetec team is exited to announce the successful reach of the next milestone by entering into the clinical study with the 4D Lifetest™.  

July 2019 - Venture Leaders Life Science - Trip to the USA was a great experience

As a awarded winner 4D Lifetec became part of the Venture Leaders Life Science Group 2019 and was invited to travel to Boston (USA).

June 2019 - 4D Lifetec flies to Boston

Arne Faisst, our CEO, tells more about our plans in the US

May 2019 – PLEASE VOTE, VOTE, VOTE - TOP 100 Swiss Startup Award 2019

Please vote for 4D Lifetec.

May 2018 - 4D Lifetest™ tumor detection and diagnostic program started

4D Lifetec AG has started the early cancer diagnostic validation program for its integral liquid biopsy assay 4D Lifetest™.

April 2017 - Preventive cancer diagnostics in focus

4D Lifetec has been recognized and selected out of approximately 200 applications for the W.A. de Vigier Start-up Award.

January 2017 - Successful finalisation of prototype phase

After some intense months the prototype phase for the 4D Lifetank has been completed by the end of 2016.

News since beginning until 2017

Are you interested in reading 4D Lifetec News from the beginning until 2017 please ask us for further information.